Oligomerix, Inc. is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity. The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/23/12 | $2,000,000 | Series A |
Durand Venture Associates Wheatley New York Partners | undisclosed |
